Testosterone Science

Media Watch

PBAC Testosterone Knock-Back ‘Scientifically and Logically Flawed’

Specific Claim Evaluated

The Therapeutic Goods Administration approved a female-specific testosterone cream in 2020 for distressing low libido in postmenopausal women, and the manufacturer is seeking judicial review of the decision not to list it on the PBS.

Primary Research Supporting or Contradicting the Claim

Hypoactive sexual desire disorder in postmenopausal women is the only evidence-based indication for testosterone in women (Davis et al., 2019).

Corrected Evidence-Based Interpretation

The report is correct. The manufacturer's statements are advocacy and do not replace the committee's published reasoning.

Rationale for Grade

The article attributes criticism of the reimbursement decision to the manufacturer and reports the approved indication accurately.

References

  1. Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID
    Supporting excerpt: "The only evidence-based indication for testosterone for women is for HSDD."

Post a Comment

Shared Decision Making

Bring the Evidence to Your Next Consultation

Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.